Literature DB >> 20640858

Diagnostic utility of immunohistochemical panel in various thyroid pathologies.

Arturs Ozolins1, Zenons Narbuts, Ilze Strumfa, Guna Volanska, Janis Gardovskis.   

Abstract

BACKGROUND: For management of thyroid nodules, distinction between benign and malignant tumours is essential. The study was performed to evaluate the diagnostic value of molecular markers in different thyroid tumours.
MATERIALS AND METHODS: Immunohistochemistry for CD56, HBME-1, COX-2, Ki-67, p53 and E-cadherin (E-CAD) was performed in 113 benign and 35 malignant thyroid lesions including 36 follicular adenomas (FA), 77 colloid goitres, 26 papillary thyroid carcinomas (PTC) and 9 follicular carcinomas (FC). The results were scored semiquantitatively by staining intensity (0-3 scale) and percentage of positive cells.
RESULTS: PTC was characterised by decreased E-CAD and CD56 expression in contrast to surrounding benign thyroid tissues. HBME-1 expression was absent in benign thyroid tissues but was notably high in PTC and occasionally in FC. The expression of E-CAD and CD56 in FA was significantly higher than in the surrounding thyroid tissues. No expression of p53 was found in any group. The expression of COX-2 was low in all lesions. The proliferation activity by Ki-67 was generally low; however, it was significantly higher in cancers.
CONCLUSIONS: The panel consisting of three markers, HBME-1, E-CAD and CD56, can be recommended as an adjunct to morphology criteria. HBME-1 is found in malignant lesions only and is the most sensitive and specific single marker in PTC. Decreased expression of E-CAD and CD56 distinguishes PTC from FA and FC. Both FA and FC are characterised by high expression of E-CAD and CD56. The practical use of Ki-67 is difficult due to low values. The role of adhesion factors in thyroid malignancies may be superior in comparison with cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20640858     DOI: 10.1007/s00423-010-0690-6

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  54 in total

1.  Thyroid incidentaloma: the ignorant in pursuit of the impalpable.

Authors:  Duncan Topliss
Journal:  Clin Endocrinol (Oxf)       Date:  2004-01       Impact factor: 3.478

2.  HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.

Authors:  Yasuhiro Ito; Hiroshi Yoshida; Chisato Tomoda; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kennichi Kakudo; Kanji Kuma; Akira Miyauchi
Journal:  Anticancer Res       Date:  2005 Jan-Feb       Impact factor: 2.480

3.  E-cadherin gene alterations are rare events in thyroid tumors.

Authors:  P Soares; G Berx; F van Roy; M Sobrinho-Simões
Journal:  Int J Cancer       Date:  1997-01-06       Impact factor: 7.396

4.  Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours.

Authors:  M Miettinen; P Kärkkäinen
Journal:  Virchows Arch       Date:  1996-11       Impact factor: 4.064

5.  Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.

Authors:  E Saggiorato; R De Pompa; M Volante; S Cappia; F Arecco; A P Dei Tos; F Orlandi; M Papotti
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

6.  Immunohistochemical expression of cyclooxygenase 2 in follicular carcinomas of the thyroid.

Authors:  Denise M Haynik; Richard A Prayson
Journal:  Arch Pathol Lab Med       Date:  2005-06       Impact factor: 5.534

7.  Immunoexpression of TTF-1 and Ki-67 in a coexistent anaplastic and follicular thyroid cancer with rare long-life surviving.

Authors:  El Ali Ziad; Marek Ruchala; Jan Breborowicz; Maciej Gembicki; Jerzy Sowinski; Marian Grzymislawski
Journal:  Folia Histochem Cytobiol       Date:  2008       Impact factor: 1.698

8.  Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.

Authors:  Ying Y Liu; Hans Morreau; Job Kievit; Johannes A Romijn; Nancy Carrasco; Johannes W Smit
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

9.  Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.

Authors:  L A Akslen; J E Varhaug
Journal:  Cancer       Date:  1995-11-01       Impact factor: 6.860

10.  HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm.

Authors:  Takahiro Mase; Hiroomi Funahashi; Takashi Koshikawa; Tsuneo Imai; Yoshiharu Nara; Yuji Tanaka; Akimasa Nakao
Journal:  Endocr J       Date:  2003-04       Impact factor: 2.349

View more
  8 in total

1.  Surgical endocrinology--update 2010.

Authors:  Bruno Niederle
Journal:  Langenbecks Arch Surg       Date:  2010-08-16       Impact factor: 3.445

2.  Utility of immunohistochemical markers in diagnosis of follicular cell derived thyroid lesions.

Authors:  Hanan AlSaeid Alshenawy
Journal:  Pathol Oncol Res       Date:  2014-03-23       Impact factor: 3.201

Review 3.  Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.

Authors:  Romans Uljanovs; Stanislavs Sinkarevs; Boriss Strumfs; Liga Vidusa; Kristine Merkurjeva; Ilze Strumfa
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

4.  E-cadherin expression is associated with susceptibility and clinicopathological characteristics of thyroid cancer: A PRISMA-compliant meta-analysis.

Authors:  Changlin Zhou; Chunsheng Yang; Daoqun Chong
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

5.  Contrast-enhanced ultrasound for the differential diagnosis of thyroid nodules: An updated meta-analysis with comprehensive heterogeneity analysis.

Authors:  Juanjuan Zhang; Xiuting Zhang; Yanna Meng; Yinghong Chen
Journal:  PLoS One       Date:  2020-04-20       Impact factor: 3.240

Review 6.  Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers.

Authors:  Rita Niciporuka; Jurijs Nazarovs; Arturs Ozolins; Zenons Narbuts; Edvins Miklasevics; Janis Gardovskis
Journal:  Medicina (Kaunas)       Date:  2021-10-19       Impact factor: 2.948

Review 7.  Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis.

Authors:  Leandro Luongo de Matos; Adriana Braz Del Giglio; Carolina Ogawa Matsubayashi; Michelle de Lima Farah; Auro Del Giglio; Maria Aparecida da Silva Pinhal
Journal:  Diagn Pathol       Date:  2012-08-13       Impact factor: 2.644

8.  Absent CD56 expression in papillary thyroid carcinoma: A finding of potential diagnostic value in problematic cases of thyroid pathology.

Authors:  Mozhgan Mokhtari; Mehdi Eftekhari; Reza Tahririan
Journal:  J Res Med Sci       Date:  2013-12       Impact factor: 1.852

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.